PriceTargets.com logo

Resverlogix - RVX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: C$0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
C$0.06 As of 04/25/2024 05:17 PM ET
▼ -0.005 (-8.33%)

This chart shows the closing price for RVX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Resverlogix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVX

Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Resverlogix in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$0.06.

This chart shows the closing price for RVX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Resverlogix. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/23/2019Roth CapitalReiterated RatingBuy
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Resverlogix logo
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada.
Read More

Today's Range

Now: C$0.06
Low: C$0.06
High: C$0.06

50 Day Range

MA: C$0.06
Low: C$0.06
High: C$0.07

52 Week Range

Now: C$0.06
Low: C$0.05
High: C$0.15

Volume

7,200 shs

Average Volume

36,842 shs

Market Capitalization

C$14.97 million

P/E Ratio

N/A

Dividend Yield

7.02%

Beta

0.78

Frequently Asked Questions

What sell-side analysts currently cover shares of Resverlogix?

The following Wall Street analysts have issued reports on Resverlogix in the last year:
View the latest analyst ratings for RVX.

What is the current price target for Resverlogix?

0 Wall Street analysts have set twelve-month price targets for Resverlogix in the last year. has the lowest price target set, forecasting a price of C$10,000,000.00 for Resverlogix in the next year.
View the latest price targets for RVX.

What is the current consensus analyst rating for Resverlogix?

Resverlogix currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for RVX.

What other companies compete with Resverlogix?

Other companies that are similar to Resverlogix include Sirona Biochem, Reunion Neuroscience, Neptune Wellness Solutions, Antibe Therapeutics and Kane Biotech. Learn More about companies similar to Resverlogix.

How do I contact Resverlogix's investor relations team?

Resverlogix's physical mailing address is 300-4820 Richard Rd SW, CALGARY, AB T3E 6L1, Canada. The biotechnology company's listed phone number is +1-403-2549252. The official website for Resverlogix is www.resverlogix.com. Learn More about contacing Resverlogix investor relations.